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Major histocompatibility complex associations
of ankylosing spondylitis are complex and involve
further epistasis with ERAP1
Adrian Cortes1, Sara L. Pulit2, Paul J. Leo1, Jenny J. Pointon3, Philip C. Robinson1, Michael H. Weisman4, Michael Ward5,
Lianne S. Gensler6, Xiaodong Zhou7, Henri-Jean Garchon8,9, Gilles Chiocchia8, Johannes Nossent10,11, Benedicte A. Lie12,13,
Øystein Førre14, Jaakko Tuomilehto15,16,17, Kari Laiho18, Linda A. Bradbury1, Dirk Elewaut19,20, Ruben Burgos-Vargas21,
Simon Stebbings22, Louise Appleton3, Claire Farrah3, Jonathan Lau3, Nigil Haroon23, Juan Mulero24, Francisco J. Blanco25,
Miguel A. Gonzalez-Gay26, C. Lopez-Larrea27,28, Paul Bowness3, Karl Gaffney29, Hill Gaston30, Dafna D. Gladman31,32,33,
Proton Rahman34, Walter P. Maksymowych35, J. Bart A. Crusius36, Irene E. van der Horst-Bruinsma37, Raphael Valle-On˜ate38,
Consuelo Romero-Sa´nchez38, Inger Myrnes Hansen39, Fernando M. Pimentel-Santos40, Robert D. Inman23, Javier Martin41,
Maxime Breban8,42, Bryan Paul Wordsworth3, John D. Reveille7, David M. Evans1,43,44, Paul I.W. de Bakker2,45
& Matthew A. Brown1
Ankylosing spondylitis (AS) is a common, highly heritable, inflammatory arthritis for which
HLA-B*27 is the major genetic risk factor, although its role in the aetiology of AS remains elusive.
To better understand the genetic basis of the MHC susceptibility loci, we genotyped 7,264
MHC SNPs in 22,647 AS cases and controls of European descent. We impute SNPs, classical
HLA alleles and amino-acid residues within HLA proteins, and tested these for association to AS
status. Here we show that in addition to effects due to HLA-B*27 alleles, several other HLA-B
alleles also affect susceptibility. After controlling for the associated haplotypes in HLA-B, we
observe independent associations with variants in the HLA-A, HLA-DPB1 and HLA-DRB1 loci. We
also demonstrate that the ERAP1 SNP rs30187 association is not restricted only to carriers of
HLA-B*27 but also found in HLA-B*40:01 carriers independently of HLA-B*27 genotype.
DOI: 10.1038/ncomms8146 OPEN
1 University of Queensland Diamantina Institute, Princess Alexandra Hospital, Brisbane 4102, Australia. 2 Department of Medical Genetics, Center for Molecular Medicine, University
Medical Center Utrecht, Utrecht 3584, The Netherlands. 3 NIHR Oxford Musculoskeletal Biomedical Research Unit, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, UK.
4Department of Medicine/Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. 5 Intramural Research Program, National Institute of Arthritis and
Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland 20892-1468, USA. 6Department of Medicine/Rheumatology, University of California, San
Francisco, California 94143, USA. 7Department of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.
8 INSERM UMR 1173, Universite´ de Versailles Saint Quentin en Yvelines, Laboratoire d’excellence Inflamex, Saint-Quentn-En-Yvelines 78180, France. 9Genetics Division, Hoˆpital
Ambroise Pare´, AP-HP, and Universite´ de Versailles Saint Quentin en Yvelines, Boulogne-Billancourt 78180, France. 10 School of Medicine, University of Western Australia, Perth, WA
6009, Australia. 11 Department of Rheumatology, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia. 12Department of Medical Genetics, University of Oslo and Oslo University
Hospital, Oslo 0310, Norway. 13Department of Immunology, Oslo University Hospital, Oslo 0310, Norway. 14Department of Rheumatology, Oslo University Hospital, and University of
Oslo, Oslo 0310, Norway. 15Department of Chronic Disease Prevention, National Institute for Health and Welfare, 00271 Helsinki, Finland. 16 Centre for Vascular Prevention, Danube-
University Krems, 3500 Krems, Austria. 17Diabetes Research Group, King Abdulaziz University, 21589 Jeddah, Saudi Arabia. 18Department of Medicine, Paijat-Hame Central Hospital,
Lahti, Finland. 19Department of Rheumatology, Gent University Hospital, Gent 9052, Belgium. 20VIB Inflammation Research Center, Ghent University, Gent 9052, Belgium.
21Department of Rheumatology, Hospital General de Mexico and Universidad Nacional Autonoma de Mexico, Mexico City 06726, Mexico. 22Department of Medicine, Dunedin
School of Medicine, University of Otago, Dunedin 9016, New Zealand. 23Division of Rheumatology, Toronto Western Hospital, University of Toronto, Toronto M5T2S8, Canada.
24Department of Rheumatology, Hospital Puerta de Hierro, Madrid 28222, Spain. 25Department of Rheumatology, Complejo Hospitalario La Corun˜a, INIBIC, La Corun˜a 15006, Spain.
26Department of Rheumatology, Hospital Marques de Valcecillas, IFIMAV, Santander 39008, Spain. 27Department of Immunology, Hospital Universitario Central de Asturias, Oviedo
33011, Spain. 28 Fundacio´n Renal ‘In˜igo A´lvarez de Toledo’, Madrid 33011, Spain. 29Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UK.
30Department of Medicine, University of Cambridge, Addenbrookes Hospital, Cambridge CB2 0SP, UK. 31 Division of Rheumatology, University of Toronto, Toronto, ON M4N 3M5,
Canada. 32 Toronto Western Research Institute, Toronto ON M4N 3M5, Canada. 33 Psoriatic Arthritis Program, University Health Network, Toronto ON M4N 3M5, Canada.
34Memorial University of Newfoundland, Newfoundland NL A1B 3X9, Canada. 35Department of Medicine, University of Alberta, Alberta T6G 2R7, Canada. 36Department of Medical
Microbiology and Infection Control, Laboratory of Immunogenetics, VU University Medical Center, Amsterdam 1081 BT, The Netherlands. 37Department of Rheumatology, VU
University Medical Centre, Amsterdam 1081 BT, Netherlands. 38 Spondyloarthropaty Group-Division of Rheumatology, Hospital Militar Central/Universidad de La Sabana, Transversal
3 # 49-00, Bogota´, NA, Colombia. 39Helgelandssykehuset, 8613 Mo i Rana, Norway. 40Chronic Diseases Research Centre (CEDOC), Faculdade de Cieˆncias Me´dicas, Universidade
Nova de Lisboa, Lisboa 1169-056, Portugal. 41 Instituto de Parasitologı´a y Biomedicina Lo´pez-Neyra, Consejo Superior de Investigaciones–Cientı´ficas, Granada 18100, Spain. 42Division
of Rheumatology, Hoˆpital Ambroise Pare´, AP-HP, and Universite´ de Versailles Saint Quentin en Yvelines, Boulogne-Billancourt 92100, France. 43MRC Integrative Epidemiology Unit,
University of Bristol, Bristol, UK. 44 School of Social and Community Medicine, University of Bristol, Bristol, UK. 45Department of Epidemiology, Julius Center for Health Sciences and
Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. Correspondence and requests for materials should be addressed to M.B. (email: matt.brown@uq.edu.au).
NATURE COMMUNICATIONS | 6:7146 | DOI: 10.1038/ncomms8146 | www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
A
nkylosing spondylitis (AS) is a common, highly heritable1,
inflammatory arthritis for which HLA-B*27 is the major
genetic risk factor. To better understand the genetic basis
of the major histocompatibility complex (MHC) susceptibility
loci, we genotyped 7,264 MHC single-nucleotide polymorphisms
(SNPs) in 9,069 AS cases and 13,578 population controls of
European descent using the Illumina Immunochip microarray. In
addition to extremely strong effects due to HLA-B*27:02 and
B*27:05, several other HLA-B alleles (B*07:02, B*13:02, B*40:01,
B*40:02, B*47:01, B*51:01 and B*57:01) also affect susceptibility to
AS. HLA-B-independent associations were demonstrated with
variants in the HLA-A, HLA-DPB1 and HLA-DRB1 loci. We also
demonstrate that the ERAP1 SNP rs30187 association is not
restricted only to carriers of HLA-B*27 but also found in HLA-
B*40:01 carriers independently of the HLA-B*27 genotype. The
presence of associations in both HLA class I and II loci might
reflect effects on antigen presentation to both CD4þ and CD8þ
T lymphocytes in the pathogenesis of AS.
While the classical HLA-B*27 allele is found in over 85% of AS
patients2–4, it is clearly not sufficient alone to cause disease, with
only 1–5% of HLA-B*27 carriers developing the disease. From
epidemiological data, it is evident that susceptibility to AS is
affected by other genes within and outside the MHC1. Indeed, 26
risk loci outside the MHC have now been identified by genome-
wide association studies5–8.
The biological mechanism(s) by which HLA-B27 confers risk of
disease remains elusive. The main hypotheses regarding this
mechanism can be divided into canonical mechanisms based on
the known function of HLA-B27 within the adaptive immune
system, and non-canonical mechanisms related to unusual
properties of HLA-B27, notably its propensity to dimerise or
misfold. Suggested canonical mechanisms propose either that
HLA-B27 is uniquely capable of presenting particular peptide(s)
found at sites of inflammation in AS to cytotoxic T lymphocytes
(the arthritogenic peptide hypothesis)9 or that HLA-B27 is
associated with reduced gut mucosal immunity, leading to
migration of enteric bacteria across the intestinal mucosa,
driving the production of the pro-inflammatory cytokine
interleukin (IL)-23 and development of AS (the mucosal
immunodeficiency hypothesis)10,11. Both these theories place
antigenic peptide presentation and handling as critical steps in
the pathogenesis of AS. One of the first non-MHC susceptibility
loci to be identified in AS was endoplasmic reticulum
aminopeptidase 1 (ERAP1)5, the main function of which is to
trim peptides in the endoplasmic reticulum (ER) to optimal length
for binding to MHC class I molecules on antigen-presenting cells
for subsequent interaction with CD8þ T cells12,13. Moreover, this
association is so far uniquely found in HLA-B*27-positive disease7.
HLA-B27 has an unusual property of forming homodimers
through disulphide bonding of the unpaired cysteine residue at
position 67 (ref. 14). It has been proposed that these homodimers
may cause AS through abnormal presentation of peptides or by
facilitating ‘abnormal’ interaction with natural killer cells15. Apart
from HLA-B*27, the subtypes of the alleles HLA-B*14, HLA-B*15,
HLA-B*38, HLA-B*39 and HLA-B*75 encode a cysteine residue at
position 67 but of these there is only evidence that HLA-B*14may
be AS associated16,17. It is also unclear if these other non-HLA-
B27 Cys67 variants can form homodimers. In addition, Cys67 is
found on all HLA-B27 subtypes, including the subtypes HLA-
B*27:06 and HLA-B*27:09, which are not AS associated18,19. A
further hypothesis suggests that abnormal folding of the HLA-
B27 molecule during assembly results in ER stress and activation
of the unfolded protein response20,21. ER stress is evident in the
HLA-B*27-transgenic rat model of AS and correlates with
production of IL-23 (ref. 21), but has not been demonstrated in
HLA-B*27-positive patients22–24.
While non-B27 HLA associations have been reported, notably
with HLA-B40 (refs 25–27) and HLA-A*02 (ref. 8), most have not
been definitive or replicated in independent studies. In this study,
we analyse the associations of AS across the MHC aiming to
identify functional and potentially causal variants using a large,
previously reported, panel of cases and controls of European
ancestry8. Here we extend on our primary analysis of this cohort
by fine mapping the MHC region with imputation of SNPs, MHC
class I and II classical alleles, and amino-acid residues within the
classical HLA proteins28. In addition to HLA-B27, we identify
further HLA-B and other HLA class I and II alleles associated
with AS, and demonstrate that HLA-B40 in addition to HLA-B27
interacts with ERAP1 to cause disease. This implicates both CD4
and CD8 lymphocytes in AS pathogenesis and suggests that
HLA-B40 and HLA-B27 operate by similar mechanisms to induce
the disease.
Results
HLA-B susceptibility alleles. At the HLA-B locus, 38 classical
alleles at four-digit resolution were imputed. All SNP, HLA and
amino-acid association P-values were determined by logistic
regression. As expected, the two common HLA-B*27 alleles
in the European population, B*27:02 (odds ratio (OR)¼ 43;
P¼ 1.07 10 122) and B*27:05 (OR¼ 62; Po10 321), were the
most significantly associated with disease risk (Fig. 1a–b;
Tables 1 and 2). Controlling for the effect of the two B*27 alleles,
we identified the protective alleles HLA-B*07:02 (OR¼ 0.82;
P¼ 5.04 10 6) and HLA-B*57:01 (OR¼ 0.75; P¼ 5.13 10 4;
Table 2). Moderate association was also observed, sequentially,
with the risk alleles HLA-B*51:01 (OR¼ 1.33; P¼ 2.14 10 3),
HLA-B*47:01 (OR¼ 2.35; P¼ 2.25 10 3), HLA-B*40:02
(OR¼ 1.59; P¼ 4.65 10 3), HLA-B*13:02 (OR¼ 1.43; P¼
4.29 10 3) and HLA-B*40:01 (OR¼ 1.22; P¼ 4.93 10 3).
No evidence of further susceptibility alleles was observed after
controlling for the risk and protective alleles identified above
(P40.05; Fig. 1d). The HLA-B associations were similar in both
HLA-B*27-positive and HLA-B*27-negative restricted analyses
(Supplementary Tables 1–6).
Non-HLA-B susceptibility loci in the MHC. To assess whether
other MHC loci affect disease susceptibility independently from
the HLA-B locus, we performed additional conditional analyses.
Adjusting for the HLA-B susceptibility alleles identified, we
observed an association signal with SNPs in the HLA-A locus
(rs2975033; OR¼ 1.22; P¼ 6.16 10 10) and with the classical
allele HLA-A*02:01 (OR¼ 1.22; P¼ 1.41 10 9; Fig. 1c–d).
The risk allele ‘A’ of rs2975033 was in near perfect linkage
disequilibrium with the risk allele HLA-A*02:01 (r2¼ 0.97).
Further controlling for the effect of the susceptibility SNP
rs2975033 in HLA-A revealed an independent signal with SNPs
(rs1126513; OR¼ 1.21; P¼ 2.46 10 7) in the class II locus
HLA-DPB1 (Fig. 1e); no association of similar strength to those
seen with SNPs (P410 5) were observed with classical HLA-
DPB1 alleles (Fig. 1f). After controlling for the effect of the SNP
rs1126513 in HLA-DPB1, we observed an association with the
SNP rs17885388 (OR¼ 1.16; P¼ 1.27 10 5) in the HLA-DRB1
locus, and a similar level of significance was also observed with
the class II allele HLA-DRB1*01:03 (P¼ 3.78 10 5). No further
associations were observed after controlling for all identified
effects (P45 10 5; Fig. 1i–j).
Association signals and amino-acid positions in HLA proteins.
We observed disease-associated alleles at MHC class I and II loci.
Classical alleles at these loci determine the amino-acid sequence
of the respective HLA proteins, which could in turn influence the
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specificity of the peptides presented to CD8þ and CD4þ
T lymphocytes. We, therefore, analysed the polymorphic amino-
acid residues at these proteins to assess their effect in disease
susceptibility. In this analysis, the strongest association was
observed for amino-acid position 97 in HLA-B (omnibus
Po10 3221; Table 1; Fig. 1a–b). In addition, through conditional
analysis, we found that the association at the HLA-B*27 allele,
and other HLA-B*27-associated polymorphisms, was explained
by position 97 while the reverse was not true (Supplementary
Table 7). This polymorphic position carries as many as six
different amino-acid residues in the population (Fig. 2),
each conferring a different degree of risk (or protection) to
disease, consistent with the analysis of HLA-B alleles mentioned
above (Table 2). Position 97 lies in the floor of the HLA-B
peptide-binding groove (Fig. 3), located in the C/F pocket,
also referred as the C-terminal pocket, which anchors the side
chain of the C-terminal peptide residue29. Asparagine at position
97 is uniquely observed in HLA-B*27 alleles. Threonine at
position 97 (predominantly found in HLA-B*51 alleles) was also
found to increase disease risk (OR¼ 1.12; P¼ 4.50 10 3);
serine (found in HLA-B*07 and *08 alleles) decreased risk of
disease (OR¼ 0.86; P¼ 5.2 10 8); and valine (found in
HLA-B*57 alleles) was also protective (OR¼ 0.68;
P¼ 1.4 10 8; Table 3).
Strong associations were also observed with the amino-acid
positions 70, 114, 77 and 67 of HLA-B but these signals were
strongly attenuated after conditioning on amino-acid position 97.
In contrast, none of these positions could explain the association
at position 97. In particular, there was little evidence of
association at position 67 (that is, the position where disulphide
bonding of unlinked cysteine residues might occur) after
conditioning on position 97 (P-value¼ 0.04; Supplementary
Table 8).
The most strongly associated amino acid of the HLA-A
molecule, after conditioning on associated HLA-B alleles,
was amino acid valine at position 95 (P¼ 3.70 10 9).
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Figure 1 | Association results with ankylosing spondylitis susceptibility in the MHC. Omnibus SNP and amino-acid association tests are shown in a, c, e,
g and i, and classical allele association tests with two- and four-digit resolution in b, d, f, h and j. The strongest association was found with positions in the
polymorphic nucleotide rs41558317 and in the polymorphic amino acid 97 of HLA-B (a), and with the HLA-B*27 allele (b). Controlling for the effect of
HLA-B susceptibility alleles, an independent association was observed with SNPs and amino-acid position in the HLA-A locus (c) corresponding to the
HLA-A*02:01 allele (d). Further conditioning on HLA-A and HLA-B loci an independent association with SNPs and amino-acid positions in the HLA-DPB1
locus was evident (e); no HLA-DPB1 classical allele was significant at the same magnitude as the SNPs and amino-acid positions (f). Further controlling for
the effect of variation in the HLA-DPB1 locus association was observed with SNPs in the HLA-DRB1 locus (g, h). SNP association tests are shown in
blue circles, colour coded by linkage disequilibrium from the SNP with the strongest association. Amino-acid position tests are shown as red triangles.
Classical allele tests are shown as bars for two- and four-digit imputation resolution.
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The association with this amino acid was statistically equivalent
with that observed with the SNP rs2975033 and with the classical
allele HLA-A*02:01. This amino acid is positioned within the
binding site of HLA-A (Fig. 3).
Independent associations were observed at the two class II loci
HLA-DPB1 and HLA-DRB1, and these were highly correlated
with polymorphic amino acids in the peptide-binding site
of these molecules (Fig. 3). At the HLA-DPB1 locus, rs1126513
showed the strongest association and the risk allele for rs1126513
was perfectly correlated with the presence of leucine at position
11 of the HLA-DPB1 molecule (position 11; OR¼ 1.21;
P-value¼ 2.46 10 7). At the HLA-DRB1 locus, the strongest
association with an amino acid was observed with aspartic acid at
position 70 (OR¼ 1.16; P-value¼ 3.44 10 5); due to linkage
disequilibrium this association was statistical equivalent to the
one observed with the SNP rs17885388.
Gene–gene interactions and susceptibility loci. We have
previously observed that the association with the variant rs30187
in the ERAP1 locus is restricted to HLA-B*27-positive subjects,
consistent with an epistatic interaction between these two loci7.
Here we investigated the possibility of interaction between the
other HLA-B susceptibility alleles and the variant rs30187. When
testing for interaction with the HLA-B*40 alleles, we found that
rs30187-T increased the risk of disease in the strata where
HLA-B*27 was present, as previously shown, or when
HLA-B*40:01 was present in the absence of HLA-B*27
(OR¼ 1.41; P¼ 5.81 10 3); rs30187 had no effect on disease
susceptibility when both HLA-B*27 and HLA-B*40 alleles were
absent or in the non-HLA-B*27/HLA-B*40:02 stratum (Fig. 4). No
evidence of interaction was observed between rs30187 and the
other HLA-B susceptibility alleles. This suggests that the rs30187
variant interacts with the HLA-B*40:01 allele; although no
evidence to support an interaction was observed with
HLA-B*40:02, the study had low power to detect such an effect.
There was no evidence of interaction between either of the
HLA-B*40 alleles and any of the other independently associated
Table 1 | Most significant polymorphic positions (omnibus test) and imputed classical alleles associated with ankylosing
spondylitis susceptibility (P-valueo1 10 2000).
Position rs AA position Classical allele v2 DF P-value
31,432,180 — 97 — 14,857 5 o10 3,221
31,432,180 rs1071652 — — 14,841 3 o10 3,221
31,430,829 rs41558317 — — 14,823 1 o10 3,221
31,432,179 rs1140412 — — 14,823 2 o10 3,219
— — — HLA-B*27 14,820 1 o10 3,221
31,432,506 — 70 — 14,812 3 o10 3,215
31,432,129 — 114 — 14,402 2 o10 3,128
31,432,130 rs709055 — — 14,401 2 o10 3,128
31,432,131 rs1050628 — — 14,389 1 o10 3,127
— — — HLA-B*27:05 14,220 1 o10 3,090
31,430,834 rs3819282 — — 13,798 1 o10 2,999
31,430,345 rs3819299 — — 13,757 1 o10 2,990
31,430,346 rs3819299 — — 13,757 1 o10 2,990
31,451,646 rs4463302 — — 12,898 1 o10 2,803
31,432,485 — 77 — 12,871 2 o10 2,795
31,432,486 rs1131217 — — 12,849 1 o10 2,793
31,377,108 rs2394967 — — 11,613 1 o10 2,524
31,381,125 rs6905036 — — 11,552 1 o10 2,511
31,432,208 rs41556113 — — 10,929 1 o10 2,376
31,432,843 rs41553720 — — 10,299 2 o10 2,237
31,432,515 — 67 — 9,741 4 o10 2,112
31,432,515 rs1071816 — — 9,725 3 o10 2,110
31,518,387 rs2844510 — — 9,525 1 o10 2,071
AA, amino acid; DF, degrees of freedom.
Table 2 | Evidence for association of HLA-B alleles with
susceptibility to ankylosing spondylitis. Effect sizes and
levels of significance were estimated in stepwise conditional
procedure, where for rounds 2 and onwards the test
conditioned on the previous alleles.
Round HLA-B allele OR (95% CI) P-value
1 27:05 62.41 (56.90–68.45) o10 321
2 27:02 43.41 (29.80–63.23) 1.07 10 122
3 07:02 0.82 (0.74–0.91) 5.04 106
4 57:01 0.75 (0.61–0.92) 5.13 104
5 51:01 1.33 (1.14–1.56) 2.14 10 3
6 47:01 2.35 (1.43–3.86) 2.25 10 3
7 40:02 1.59 (1.19–2.14) 4.65 10 3
8 13:02 1.43 (1.14–1.80) 4.29 10 3
9 40:01 1.22 (1.06–1.40) 4.93 10 3
All other alleles 40.05
CI, confidence interval; OR, odds ratio;
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Figure 2 | Amino-acid residue frequencies in 13,578 controls
and 9,069 cases within associated amino-acid positions within HLA
proteins.
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Table 3 | Haplotype analysis of SNPs encoding the amino acid 97 of HLA-B.
HLA-B codon 97 position
1 2 3
SNP rs41558317 rs1140412 rs1071652 rs41556417 Amino-acid
residue
Position (HG18) 31,430,829 31,432,179 31,432,180 31,432,181
Reference allele or
amino acid in HG18
A G C T Serine (S)
Alternate allele(s) G C/A G/A/T A/C
Allele frequency in
controls (ref/alt(s))
0.95/0.05 0.29
0.67/0.05
0.82
0.10/0.04/
0.05
0.92
0.04/0.04
Single locus
univariate P-value
o10 3221 o10 3219 o10 3221 2.10 10 65 Multivariate OR
(95% CI)
Unadjusted
haplotype
frequency
P HLA-B Allele
Risk allele
univariate OR
(95% CI)
60.36
(55.47–
65.74)
59.99
(55.13–
65.33)
59.99
(55.14–
65.34)
2.03 (1.86–
2.21)
Controls Cases
Haplotype G/A A T T Asparagine
(N)
16.51 (15.43–17.69) 0.045 0.449 o10 300 *27:02
*27:04
*27:05
G/A C G T Threonine
(T)
1.12 (1.03–1.21) 0.097 0.065 4.50 10 3 *13:02 *39:06
*40:06
*51:01 *51:08
*52:01 *55:01
*56:01
G/A C C T Arginine
(R)
1.00 (Reference) 0.493 0.297 1 *15:01 *15:03
*15:10
*15:16 *15:17
*15:18
*18:01 *35:01
*35:02
*35:03
*35:08 *35:12
*37:01
*38:01 *38:02
*39:01
*39:10 *40:01
*41:01
*44:02
*44:03
*44:04
*44:05
*45:01 *47:01
*49:01 *50:01
*53:01 *58:01
G/A C C A Tryptophan
(W)
1.00 (0.89–1.12) 0.042 0.025 0.95 *14:01 *14:02
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Figure 3 | Three-dimensional models for the HLA-B, HLA-A and HLA-DPb1 proteins. Three-dimensional models for the (a) HLA-B, (b) HLA-A and (c)
HLA-DPB1 proteins. These structures are based on Protein Data Bank entries 3LV3, 3UTQ and 3LQZ, respectively, with a direct view to the peptide-binding
groove.
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susceptibility SNPs in the loci encoding the aminopeptidases
ERAP1, ERAP2 and NPEPPS (P40.1).
We then examined whether our data supported a model where
the HLA-B*27 and HLA-B*40 alleles increased disease suscept-
ibility beyond their inferred independent effects, as previously
reported30. No support for an interaction between these alleles
was observed in this data set (Supplementary Table 1).
Discussion
Independently of the expected HLA-B associations, this study
demonstrates that both HLA-B*40:01 and -B*40:02 are disease
associated alleles, and identified three further HLA-B risk alleles,
HLA-B*51:01, B*47:01 and B*13:02. The allele HLA-B*51:01 is
also the major genetic risk factor for Behc¸et’s disease31,
a seronegative disease complicated by sacroiliitis resembling
AS in up to 10% of cases32. In addition to the seven HLA-B
risk alleles, we identified two protective alleles at this locus,
HLA-B*07:02 and HLA-B*57:01. Interestingly, in the HLA-B*27-
transgenic rat model of AS, the HLA-B*27-negative control
carries the HLA-B*07 allele, and does not develop disease,
consistent with the protective effect of this allele in humans33.
It has recently been shown in HLA-B7/B27 co-expressing
mice that there is partial negative selection of HLA-B27þ
T cells in the course of defining the immunodominant response
to influenza infection34. Further, in Erap-deficient, influenza-
infected HLA-B27-positive mice, there was a marked reduction in
presentation of the HLA-B27 immunodominant epitope, and
T-cell immunity to that epitope, presumed to be because the
HLA-B27-related immunodominant flu epitope requires cleavage
by Erap to be presented by HLA-B27. In contrast, in HLA-B7-
transgenic mice, Erap deficiency had no effect on presentation of
the HLA-B7 immunodominant epitope or the corresponding
T-cell response to it, suggesting that it does not require Erap
cleavage for presentation35. This provides a potential mechanism
to explain the genetic effects observed in humans with AS, with
ERAP1 loss of function protecting against HLA-B27-associated
AS, but having no effect in HLA-B7 carriers, where an HLA-B7
protective association is observed.
Outside the HLA-B locus, we identified three independent
significant signals associated with AS; one was in the HLA class I
locus HLA-A, and one each in the HLA class II loci HLA-DPB1
and HLA-DRB1. The association in the HLA-A locus corre-
sponded to the classical allele HLA-A*02:01, which has also been
implicated in multiple sclerosis36; however, while this allele is
protective in multiple sclerosis, it increases the risk of AS.
Previous studies have hinted at HLA-DPB1 associations with AS,
which we have confirmed here. HLA-DPB1, in conjunction with
HLA-DPA1, forms the HLA-DP heterodimer, which typically
plays a role in the presentation of exogenously derived peptides,
such as microbial peptides, to CD4þ T lymphocytes. The
strongest association was found with an amino-acid position
located in the base of the peptide-binding groove of HLA-DP,
suggesting that this polymorphism might impact on the peptide
repertoire presented by HLA-DP.
Previous findings that ERAP1 variants influence risk of disease
in HLA-B*27 positive, but not negative individuals, strongly
support the notion that both these molecules act in the same
biological pathway to affect disease susceptibility7. We have now
shown that HLA-B*40:01 interacts with ERAP1 variants in the
same manner. Similar genetic interactions involving ERAP1 have
been observed in two other immune-mediated disorders—
psoriasis with HLA-Cw6 (ref. 37) and Behc¸et’s syndrome with
HLA-B*51 (ref. 38), two disorders that are already known to share
genetic susceptibility factors with AS. It is likely that the similar
molecular mechanisms are involved in these disorders, and that
these include the pathways of MHC class I antigen presentation.
To our knowledge, there is no evidence that HLA-B40, HLA-B51
or HLA-Cw6 have non-canonical disease-related properties such
as those by which HLA-B27 is proposed to function in the
pathogenesis of AS.
Analysis of polymorphic amino-acid positions in these AS-
associated HLA molecules showed that the SNPs with the
strongest evidence of association at each of these three loci were
highly associated with amino-acid positions located in the
peptide-binding groove of these proteins. From these results, we
infer that antigen presentation to both CD4þ and CD8þ T
lymphocytes is likely to be important in the pathogenesis of AS
and/or its tissue specificity, although other mechanisms under-
lying the associations cannot formally be excluded.
MHC class I molecules contain six specificity pockets in the
peptide-binding groove, alphabetically named A to F, which serve
to anchor particular side chains of the bound peptide39. Position
97 of HLA-B is located in the C/F pocket, also referred to as the
C-terminal pocket, which anchors the side chain of the
C-terminal peptide residue29. Experimental evidence suggests
that this position is important for protein function and shaping
the peptide repertoire presented by HLA-B. Mutagenesis
experiments have shown that Asn97 is important for HLA-
B*27:04 surface expression; mutating this residue from Asn97 to
Asp97 results in reduced surface expression and increased
accumulation of unfolded protein in the ER, as well as reduced
homodimers formation40; thus, Asn97 relative to Asp97 reduces
ER stress and B27 homodimer formation, yet is associated with
AS risk. Moreover, work in the mouse homologue has shown that
changing residue 97 (W97R) results in altered peptide specificity
and affinity for b2-microglobulin41, and previous crystallographic
studies of viral peptides bound to HLA-B27 have shown that this
position influences the location of the peptide in the binding
groove of the molecule42. Last, this position was also found to be
associated with HIV-1 viral control, where Val97 was found to
provide the strongest protective effect to progression to AIDS,
hypothesized to be through a mechanism of peptide
presentation43. Asp97 is not shared by the AS-associated
subtype HLA-B*27:07, where it is substituted by serine. Serine
is also a polar amino acid and the substitution would be expected
to have only minor effects on the protein structure. While AS is
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known to occur in individuals carrying HLA-B*27:07, its relative
strength of association compared with other AS-associated HLA-
B*27 subtypes is unknown.
In summary, with high-density genotyping of the MHC, we
have demonstrated independent association signals located in
HLA class I and II loci. Imputation of amino-acid residues in the
classical HLA class I and II proteins resolved the peak of
association at each of these loci to an amino-acid residue located
in the peptide-binding groove of these proteins. Refining this
analysis by imputation of classical HLA alleles showed that there
are multiple risk and protective haplotypes in the HLA-B locus.
Further, epistatic interaction was demonstrated between ERAP1
and the HLA class I alleles HLA-B*27 and HLA-B*40:01.
Methods
Sample collection. All cases met the modified New York classification criteria for
AS44. Nine thousand sixty-nine cases and 13,578 controls were recruited through a
multi-center study coordinated by the International Genetics of Ankylosing
Spondylitis Consortium8, and all samples were unrelated and met European
ancestry criteria as detailed therein. All subjects provided written informed consent
and the study was approved by the Princess Alexandra Hospital Research Ethics
Committee (reference HREC/05/QPAH/221) and University of Queensland
Research Ethics Committee (Project Clearance No: 2006000102). All samples were
genotyped with the Illumina (San Diego, CA, USA) Infinium platform
Immunochip45, and the current study was restricted to 7,264 markers in the MHC
(chromosome 6, bps 29,602,876–33,268,403, NCBI Build 36 human genome
coordinates).
Imputation. We imputed SNPs across the MHC, and classical HLA class I and II
alleles (HLA-A, HLA-C, HLA-B, HLA-DRBI, HLA-DQA1, HLA-DQB1, HLA-DPA1
and HLA-DPB1) and their corresponding amino acids determinants with
SNP2HLA28. Samples with cumulative dosage above 2.5, across all four-digit alleles
for any one of the HLA loci, were removed from the analysis. SNPs, alleles or
amino-acid residues were excluded from the analysis if the r2 imputation quality
score was below 0.2.
Classical allele imputation at the HLA-B locus resulted in high-quality data,
with a median sensitivity and specificity for imputed HLA-B alleles of 0.958 and
0.998, respectively (Supplementary Fig. 1). With our imputation strategy, similar
imputation performance has previously been shown for the other HLA class I and
II loci (HLA-A, HLA-C, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1 and
HLA-DPB1), suggesting that imputation performance for these loci was also
accurate in our study28,43,46,47.
Statistical framework for association analysis. Associations of SNPs, HLA
protein amino-acid positions and non-HLA-B alleles across the MHC locus were
assessed with logistic regression, assuming an additive risk effect on the log-odds
scale. To account for population stratification, we included as covariates 10 prin-
cipal components for each individual, computed with 16,145 unlinked autosomal,
non-MHC, SNPs with the tool shellfish (http://www.stats.ox.ac.uk/Bdavison/
software/shellfish/shellfish.php). The omnibus association test compares, via like-
lihood ratio test, the null model H0, where there is no risk effect at the position
tested, against the alternative model H1, where the risk effect at the position is
included in the model as a fixed effect:
H0 : logit yið Þ ¼ yþ
X10
k¼1
pkpi;k ð1Þ
H1 : logit yið Þ ¼ yþ
Xm 1
a¼1
baga;i þ
X10
k¼1
pkpi;k; ð2Þ
where yi denotes the binary phenotype code for individual i (0¼ control and
1¼ case). The pk parameter is the effect associated with each of the principal
components and pi,k is the value of the kth principal component for individual i .
The y parameter represents the sampling fraction (that is, the logistic regression
intercept). In the alternative model, a indicates the specific allele being tested and
ga,i is the dosage (imputed or genotyped) of allele a in individual i. The ba para-
meter represents the effect on the log odds of disease per allele. For testing a multi-
allelic locus, nucleic or amino-acid positions, with m possible alleles we included
m-1 b parameters, one for each allele, where the most common allele was selected
as the reference allele. The likelihood ratio test that compares model H0 with H1
results in a test statistic that is w2 distributed with m-1 degrees of freedom.
When testing for association with imputed classical HLA alleles, we defined a
series of binary markers coding the presence or absence of the allele being tested,
and each different allele was tested as a biallelic position as described above.
To identify independent effects. we performed conditional logistic regression by
including the most strongly associated position/polymorphism as a fixed effect in
both the null model H0 and the alternative model H1. We then analysed all
positions as described above. Conditional analysis was repeated in an iterative
fashion by sequentially adding the most significant positions as fixed effects until
no significant position or polymorphism was observed. Allelic associations were
deemed significant with Po10 5, this statistical significance threshold accounted
for 5,000 independent tests using Bonferroni correction. Two tests were considered
independent if the two SNPs had a pairwise correlation (r2)o0.90, which resulted
in 3,252 SNPs independent tests. For the special case of HLA-B alleles where we
had a higher prior probability of association, we defined significance as Po10 3 as
only 38 alleles were tested.
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